A photo of Joseph G. Pressey.

Joseph G. Pressey, MD

  • Director, Musculoskeletal Tumor Center
  • Co-Director, Young Adult Oncology Program
  • Co-Director, Research Solid Tumor Program
  • Professor, UC Department of Pediatrics

About

Biography

Dr. Pressey graduated from the University of Georgia and the Medical College of Georgia before pursuing pediatrics residency training at Cincinnati Children's Hospital Medical Center. He trained in pediatric hematology-oncology at the Children's Hospital of Philadelphia where he developed a keen interest in the biology and therapy of pediatric sarcomas. He spent 11 years at the University of Alabama at Birmingham School of Medicine and Children's Hospital of Alabama where he functioned as the principal investigator (PI) for the Children's Oncology Group (COG) Phase 1 and Pilot Consortium and the Sarcoma Alliance for Research through Collaboration (SARC).

Dr. Pressey joined the Cancer and Blood Diseases Institute at Cincinnati Children's to direct the Sarcoma and Young Adult Oncology Programs in 2014. He is appointed Professor of Clinical Pediatrics at the University of Cincinnati College of Medicine and functions as the Cincinnati Children's Institutional PI for the COG Pediatric Early Phase Clinical Trials Network (PEP-CTN) and SARC, as well as, for many industry-sponsored trials.

MD: Medical College of Georgia, Augusta, GA, 1995.

Residency: Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 1998.

Fellowship: Pediatric Hematology-Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, 2001.

Certification: Pediatric Hematology-Oncology, 2002.

Interests

Pediatric and young adult patients with musculoskeletal tumors including rhabdomyosarcoma and other soft-tissue sarcomas; desmoid tumors; Ewing sarcoma; osteosarcoma; pediatric solid tumors; rare tumors including small cell carcinoma of the ovary

Services and Specialties

Cancer and Blood Diseases, Sarcoma, Young Adult Cancer, Neurofibromatosis

Interests

The development of novel therapies for pediatric sarcomas and rare tumors.

Research Areas

Oncology, Cancer and Blood Diseases

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Selected

Challenges in the Treatment of Sarcomas of Adolescents and Young Adults. Rotz, SJ; Nagarajan, R; Sorger, JI; Pressey, JG. Journal of Adolescent and Young Adult Oncology. 2017; 6:406-413.

Chemotherapy-induced thrombocytopenia in Ewing sarcoma: Implications and potential for romiplostim supportive care. Merjaneh, N; Young, J; Mangoli, A; Olsen, M; Setty, B; Lane, A; Nagarajan, R; Pressey, JG; Turpin, B. Pediatric Blood and Cancer. 2022; 69.

GIST presenting as refractory iron-deficiency anaemia in paediatric patient. Al Atrash, E; Abdullah, MF; Pressey, J; Mohan, S. BMJ Case Reports. 2022; 15.

Comparison of 0.3-mSv CT to Standard-Dose CT for Detection of Lung Nodules in Children and Young Adults With Cancer. Thapaliya, S; Gilligan, LA; Brady, SL; Anton, CG; Crotty, EJ; Nasser, MP; Geller, JI; Pressey, JG; Zhang, B; Dillman, JR; et al. American Journal of Roentgenology. 2021; 217:1444-1451.

Novel ARHGAP23-FER fusion in a metastatic spindle cell-predominant neoplasm with a myofibroblastic phenotype and a sustained metabolic response to lorlatinib. Sadaf, A; Szabo, S; Ferguson, K; Sorger, JI; Sumegi, J; Bridge, JA; Pressey, JG. Cancer. 2021; 127:4124-4130.

Active and Protected: Developing a "Safer Sex " Handout for Adolescents and Young Adults with Cancer. McGrady, ME; Bredenberg, DL; Danziger-Isakov, L; Rios, J; Frias, O; West, MY; Fisher, P; Salloum, R; Pressey, JG; Norris, RE. Journal of Adolescent and Young Adult Oncology. 2021; 10:351-354.

Targeting EYA3 in Ewing Sarcoma Retards Tumor Growth and Angiogenesis. Wang, Y; Pandey, RN; Roychoudhury, K; Milewski, D; Kalin, TV; Szabo, S; Pressey, JG; Hegde, RS. Molecular Cancer Therapeutics. 2021; 20:803-815.

FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma. Milewski, D; Shukla, S; Gryder, BE; Pradhan, A; Donovan, J; Sudha, P; Vallabh, S; Pyros, A; Xu, Y; Barski, A; et al. Oncogene. 2021; 40:2182-2199.

ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. Geller, JI; Pressey, JG; Smith, MA; Kudgus, RA; Cajaiba, M; Reid, JM; Hall, D; Barkauskas, DA; Voss, SD; Cho, SY; et al. Cancer. 2020; 126:5303-5310.

Genome-Driven Therapy for Chemotherapy-Resistant Metastatic CDK6-Amplified Osteosarcoma. Lazow, MA; Johnson, SL; Johnson, ND; Breneman, JC; Dexheimer, PJ; Szabo, S; Pressey, JG. JCO Precision Oncology. 2020; 4:498-504.

From the Blog


The Challenges of Cancer Therapy in Adolescents and Young Adults
BlogCancer and Blood Diseases

The Challenges of Cancer Therapy in Adolescents and Young Adults

By Joseph Pressey, MD3/29/2018

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey